Home
About Us
Management
Technology & Products
Electroceuticals®
EFFECT Trial
SofPulse® Electroceutical® Therapy
Scientific Studies
Patents
Investors
Overview
Regulation A Offering
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Home
About Us
Management
Technology & Products
Electroceuticals®
EFFECT Trial
SofPulse® Electroceutical® Therapy
Scientific Studies
Patents
Investors
Overview
Regulation A Offering
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Management
Kodenbushi
Investors
Overview
Regulation A Offering
Regulation A Offering
News / Events
Press Releases
Email Alerts
Company Information
Profile
Management Team
Scientific Advisory Board
Presentations
IR Contacts
FAQ
Video
Financial Information
Quarterly Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Email Alerts
Presentations
Tear Sheet
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Dec 13, 2022 • 9:11 AM EST
Endonovo Launches Telehealth Initiative
Nov 30, 2022 • 9:07 AM EST
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
Nov 17, 2022 • 9:07 AM EST
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
Nov 7, 2022 • 9:07 AM EST
Endonovo Therapeutics Issues Corporate Update
Sep 27, 2022 • 1:52 PM EDT
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
Jul 28, 2022 • 9:08 AM EDT
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
Jul 21, 2022 • 11:30 AM EDT
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
Jun 9, 2022 • 2:02 PM EDT
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
Apr 25, 2022 • 9:08 AM EDT
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
Apr 11, 2022 • 9:08 AM EDT
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
<< Previous
1
2
3
4
5
6
7
8
9
10
...16
Next >>
Show All